After meeting with a key opinion leader in the gastroenterology field, Raymond James analyst Rahul Sarugaser is staying bullish on biotech company Eupraxia Pharmaceuticals (Eupraxia Pharmaceuticals Stock Quote, Charts, News, Analysts, Financials TSX:EPRX). Sarugaser reiterated an “Outperform” rating on EPRX in a Monday report as well as a maintained 12-month target price of $9.00 per […]
RenovoRx has a big upside, says Roth CapitalRoth Capital Partners analyst Scott R. Henry says he’s encouraged by new clinical results from biopharm company RenovoRx Inc (Renovo Stock Quote, Charts, News, Analysts, Financials NASDAQ:RNXT). Henry provided an update to clients on the company in a Friday note where he reiterated a “Buy” rating on the stock and 12-month price target of US$11.00. […]